DK605786A - Stabiliserede human-vaevsplasminogenaktivator-praeparater - Google Patents

Stabiliserede human-vaevsplasminogenaktivator-praeparater

Info

Publication number
DK605786A
DK605786A DK605786A DK605786A DK605786A DK 605786 A DK605786 A DK 605786A DK 605786 A DK605786 A DK 605786A DK 605786 A DK605786 A DK 605786A DK 605786 A DK605786 A DK 605786A
Authority
DK
Denmark
Prior art keywords
plasminogen activator
human tissue
tissue plasminogen
stabilized human
activator preparations
Prior art date
Application number
DK605786A
Other languages
English (en)
Other versions
DK174203B1 (da
DK605786D0 (da
Inventor
William Franklin Bennett
Stuart Elliot Builder
Larry Alan Gatlin
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25205495&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK605786(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of DK605786D0 publication Critical patent/DK605786D0/da
Publication of DK605786A publication Critical patent/DK605786A/da
Application granted granted Critical
Publication of DK174203B1 publication Critical patent/DK174203B1/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
DK198606057A 1985-12-17 1986-12-16 Stabiliserede human-vævsplasminogenaktivator-præparater DK174203B1 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/811,081 US4777043A (en) 1985-12-17 1985-12-17 Stabilized human tissue plasminogen activator compositions
US81108185 1985-12-17

Publications (3)

Publication Number Publication Date
DK605786D0 DK605786D0 (da) 1986-12-16
DK605786A true DK605786A (da) 1987-06-18
DK174203B1 DK174203B1 (da) 2002-09-16

Family

ID=25205495

Family Applications (1)

Application Number Title Priority Date Filing Date
DK198606057A DK174203B1 (da) 1985-12-17 1986-12-16 Stabiliserede human-vævsplasminogenaktivator-præparater

Country Status (23)

Country Link
US (2) US4777043A (da)
EP (1) EP0228862B1 (da)
JP (2) JPH0714886B2 (da)
KR (1) KR950010322B1 (da)
AT (1) ATE79273T1 (da)
AU (1) AU600246B2 (da)
DD (1) DD255477A5 (da)
DE (2) DE3686410T2 (da)
DK (1) DK174203B1 (da)
ES (1) ES2044840T3 (da)
FI (1) FI88873C (da)
FR (1) FR2591485B1 (da)
GB (1) GB2184354B (da)
GR (1) GR3006078T3 (da)
HU (1) HU200101B (da)
IE (1) IE59060B1 (da)
IL (1) IL80904A (da)
MY (1) MY102185A (da)
NO (1) NO168988C (da)
NZ (1) NZ218612A (da)
PH (1) PH24716A (da)
PT (1) PT83933B (da)
ZA (1) ZA869457B (da)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1267602A (en) * 1985-09-10 1990-04-10 Fumio Kakimoto Composition containing tissue plasminogen activator
JPH0672105B2 (ja) * 1985-10-02 1994-09-14 持田製薬株式会社 血栓溶解剤及びその製法
US5453363A (en) * 1985-10-23 1995-09-26 Boehringer Mannheim Gmbh Process for the activation of t-PA or Ing after genetic expression in prokaryotes
US5034225A (en) * 1985-12-17 1991-07-23 Genentech Inc. Stabilized human tissue plasminogen activator compositions
JP2708749B2 (ja) 1987-08-10 1998-02-04 エーザイ株式会社 修飾型ｔＰＡ含有注射用組成物
DE3877529T2 (de) * 1987-10-23 1996-11-07 Centre Regional De Transfusion Herstellung von hoch-gereingtem menschlichen Faktor IX sowie anderem Plasmaproteinkonzentrat und dessen therapeutische Verwendung.
US4898826A (en) * 1987-12-10 1990-02-06 Invitron Corporation Method to solubilize tissue plasminogen activator
HU206367B (en) * 1988-04-30 1992-10-28 Sandoz Ag Process for producing acid addition salts of steroid carboxylic acid-amidated taurine and glycine, as well as pharmaceutical compositions comprising such salts
US4980165A (en) * 1989-01-27 1990-12-25 Genetics Institute, Inc. Pharmaceutical formulations of plasminogen activator proteins
DE3903581A1 (de) * 1989-02-07 1990-08-16 Boehringer Mannheim Gmbh Gewebs-plasminogenaktivator-derivat
JP2520975B2 (ja) * 1989-09-21 1996-07-31 三井東圧化学株式会社 組織プラスミノ―ゲンアクチベ―タ―若しくはその誘導体を含有する血栓溶解剤
US6207151B1 (en) * 1989-09-21 2001-03-27 Mitsui Chemicals Inc. Aqueous solution of t-PA
DE3942142A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh Stabilisierung von glykosyliertem t-pa
DE3942145A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh T-pa-solubilisierung
DE3942141A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh K2p pro-stabilisierung
DE3942144A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh Stabilisierung von k1k2p pro
DE3942143A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh T-pa pro stabilisierung
US5358708A (en) * 1993-01-29 1994-10-25 Schering Corporation Stabilization of protein formulations
US5656730A (en) * 1995-04-07 1997-08-12 Enzon, Inc. Stabilized monomeric protein compositions
DE19606551C2 (de) * 1996-02-22 2000-06-08 Basotherm Gmbh rt-PA zur Prävention des Nachstars nach Kataraktoperation
US5972912A (en) * 1998-12-17 1999-10-26 S.P. Pharmaceuticals Method for lyophilizing ifosfamide
JP2003507388A (ja) * 1999-08-17 2003-02-25 ノボ ノルディスク アクティーゼルスカブ 凍結乾燥したケーキの安定化
US6586574B1 (en) 1999-08-17 2003-07-01 Nn A/S Stabilization of freeze-dried cake
HU226202B1 (en) * 1999-11-04 2008-06-30 Genentech Inc Reversed-phase hplc assay for plasminogen activators
US7282219B2 (en) 2000-03-31 2007-10-16 Kirin Beer Kabushiki Kaisha Powdery preparation for transmucosal administration containing a polymeric form of drug and exhibiting improved storage stability
US20030077682A1 (en) * 2001-09-07 2003-04-24 Hung Paul Porwen Human tissue urokinase type plasminogen activator formulation
US20110179558A1 (en) * 2009-07-29 2011-07-28 International Enviroguard Systems, Inc. Breathable Protective Fabric and Garment
EP3693021A1 (en) * 2013-03-14 2020-08-12 Allergan, Inc. Composition of a sustained-release delivery and method of stabilizing proteins during fabrication process

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK98833C (da) * 1961-04-25 1964-05-25 Novo Terapeutisk Labor As Fremgangsmåde til stabilisering af terapeutisk anvendelige plasminopløsninger.
EP0112940B1 (en) * 1982-12-30 1986-10-15 Kowa Company, Ltd. Method of producing a tissue plasminogen activator and composition comprising same
JPS59196824A (ja) * 1983-04-21 1984-11-08 Kowa Co 吸着防止剤
EP0156169B1 (en) * 1984-02-29 1991-12-18 Asahi Kasei Kogyo Kabushiki Kaisha An aqueous solution of a tissue plasminogen activator dissolved therein at an increased concentration and a method
FR2581652B1 (fr) * 1985-04-22 1989-12-22 Genentech Inc Nouveaux mutants de l'activateur tissulaire du plasminogene humain
PT82647B (pt) * 1985-05-28 1989-01-30 Wellcome Found Processo para a preparacao de uma solucao parenteral aquosa de activador de plasminogeneo de tecido
US4929444A (en) * 1985-05-28 1990-05-29 Burroughs Wellcome Co. Low pH pharmaceutical formulation containing t-PA
ZW14486A1 (en) * 1985-07-29 1986-10-22 Smithkline Beckman Corp Pharmaceutical dosage unit
CA1267602A (en) * 1985-09-10 1990-04-10 Fumio Kakimoto Composition containing tissue plasminogen activator
JPH0672105B2 (ja) * 1985-10-02 1994-09-14 持田製薬株式会社 血栓溶解剤及びその製法
DE3537708A1 (de) * 1985-10-23 1987-04-23 Boehringer Mannheim Gmbh Verfahren zur aktivierung von t-pa nach expression in prokaryonten
JPS62120321A (ja) * 1985-11-20 1987-06-01 Eisai Co Ltd ｔＰＡ含有医薬組成物
JPS62283932A (ja) * 1986-05-29 1987-12-09 Green Cross Corp:The 組織プラスミノ−ゲンアクチベ−タの乾燥製剤

Also Published As

Publication number Publication date
AU600246B2 (en) 1990-08-09
EP0228862A3 (en) 1988-09-28
EP0228862A2 (en) 1987-07-15
ATE79273T1 (de) 1992-08-15
IL80904A (en) 1992-01-15
NO865079L (no) 1987-06-18
FI865159A (fi) 1987-06-18
FR2591485B1 (fr) 1989-07-28
AU6661086A (en) 1987-06-18
NO168988C (no) 1992-04-29
US4908205A (en) 1990-03-13
PT83933B (pt) 1989-01-17
ZA869457B (en) 1988-08-31
JPH07173076A (ja) 1995-07-11
EP0228862B1 (en) 1992-08-12
PT83933A (en) 1987-01-01
DE3686410D1 (de) 1992-09-17
KR870005647A (ko) 1987-07-06
FR2591485A1 (fr) 1987-06-19
JPH0714886B2 (ja) 1995-02-22
ES2044840T3 (es) 1994-01-16
NO865079D0 (no) 1986-12-16
HUT42955A (en) 1987-09-28
IE863279L (en) 1987-06-17
DK174203B1 (da) 2002-09-16
NZ218612A (en) 1989-07-27
KR950010322B1 (ko) 1995-09-14
NO168988B (no) 1992-01-20
GR3006078T3 (da) 1993-06-21
HU200101B (en) 1990-04-28
JPS62164632A (ja) 1987-07-21
IE59060B1 (en) 1993-12-15
PH24716A (en) 1990-10-01
FI865159A0 (fi) 1986-12-17
DD255477A5 (de) 1988-04-06
DE3642960A1 (de) 1987-06-19
DK605786D0 (da) 1986-12-16
DE3686410T2 (de) 1993-02-18
IL80904A0 (en) 1987-03-31
GB2184354A (en) 1987-06-24
GB8629981D0 (en) 1987-01-28
MY102185A (en) 1992-04-30
FI88873B (fi) 1993-04-15
FI88873C (fi) 1993-07-26
GB2184354B (en) 1990-04-11
US4777043A (en) 1988-10-11

Similar Documents

Publication Publication Date Title
DK605786A (da) Stabiliserede human-vaevsplasminogenaktivator-praeparater
GR3023825T3 (en) Benzopyran derivatives, processes for their preparation and their use and preparations containing the compounds
NO862096L (no) Fremgangsmaate for fremstilling av farmasoeytiske preparater inneholdende vevsplasminogenaktivator.
GR3019514T3 (en) Pharmaceutical preparation for the treatment of prolonged coagulation time
DK0482097T3 (da) Tensidpræparater og fremgangsmåder
NO921382D0 (no) Amidinofenylalaninderivater, samt fremstilling, anvendelse og preparater inneholdende forbindelsene
IL85189A (en) Beta-alkyl substituted melatonins,their preparation and pharmaceutical compositions containing them
PT89742A (pt) Processo de preparacao de 24r-cimnol e de suas composicoes farmaceuticas
MY102026A (en) Antiasthmatic.
DK630088D0 (da) Azelastinembonat, fremgangsmaade til fremstilling deraf og farmaceutiske praeparater med indhold af denne forbindelse som aktivt middel
GR3005231T3 (da)
AU1235288A (en) Antidepressant compositions
TR22867A (tr) Birden fazla aktif bilesen ihtiva eden insektisid terkibi
SE8503513L (sv) Farmaceutiska och kosmetiska kompositioner, vilka som verksam bestandsdel innehaller acetyl-10-triacetoxi-1,8,9-antracen
GR3003132T3 (en) Pharmaceutical compositions having healing activity
IL68195A (en) Dermatological preparations containing as active ingredients 1alpha-hydroxycholecalciferol or 1alpha,25-dihydroxy-cholecalciferol
ES8706441A1 (es) Procedimiento para preparar una composicion farmaceutica a base de sulpirida y un progestageno.
DK98788D0 (da) Benzylaminoaryl-dihydropyridinlactoner, fremgangmsaade til deres fremstilling samt deres anvendelse som laegemidler

Legal Events

Date Code Title Description
B1 Patent granted (law 1993)
PUP Patent expired